Leishmania antimony resistance: what we know what we can learn from the field.
about
Multilocus microsatellite typing of Leishmania and clinical applications: a reviewComparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmaniaImmunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swellingMiltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in ColombiaComparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant StrainAllopurinol Resistance in Leishmania infantum from Dogs with Disease RelapseDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinentLeishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.Transmission potential of antimony-resistant leishmania field isolatesDevelopments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.Correlation between glucose uptake and membrane potential in Leishmania parasites isolated from DCL patients with therapeutic failure: a proof of concept.A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts.Simple HPLC-UV for the quantification of a new leishmanicidal candidate (E)-1-4(trifluoromethyl) benzylidene)-5-(2-4-dichlorozoyl) carbonylhydrazine (LASSBio-1736) in rat plasma for pharmacokinetics assessment.Atypical Manifestations of Cutaneous Leishmaniasis in a Region Endemic for Leishmania braziliensis: Clinical, Immunological and Parasitological Aspects.Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.Synthesis and structure-activity relationships of lansine analogues as antileishmanial agents.Iron in intracellular infection: to provide or to deprive?Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.Antimony resistance and environment: Elusive links to explore during Leishmania life cycle."Drug resistance associated membrane proteins".Antileishmanial activity of diterpene acids in copaiba oil.Mechanisms of action of substituted β-amino alkanols on Leishmania donovani.Evaluating drug resistance in visceral leishmaniasis: the challenges.Leishmania major protein disulfide isomerase as a drug target: enzymatic and functional characterization.Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.Expression Analysis of Multiple Genes May Involve in Antimony Resistance among Leishmania major Clinical Isolates from Fars Province, Central Iran.Ruthenium-Clotrimazole complex has significant efficacy in the murine model of cutaneous leishmaniasis.Cross-resistance of Leishmania infantum isolates to nitric oxide from patients refractory to antimony treatment, and greater tolerance to antileishmanial responses by macrophages.Randomized, double-blind, controlled, comparative study on intralesional 10% and 15% hypertonic saline versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis.An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.Biocompatibility of antimicrobials to maggot debridement therapy: medical maggots Lucilia sericata (Diptera: Calliphoridae) exhibit tolerance to clinical maximum doses of antimicrobials.Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.Treatment with triterpenic fraction purified from Baccharis uncinella leaves inhibits Leishmania (Leishmania) amazonensis spreading and improves Th1 immune response in infected miceComparison of hydrocarbon-and lactam-bridged cyclic peptides as dimerization inhibitors of Leishmania infantum trypanothione reductase
P2860
Q22810163-2DAD2A9A-ECCD-4E7E-9BA4-3E86793E2C93Q27009505-1AF015A9-CE4A-49FC-9ABC-C275F6E6A22BQ28480593-AEEE307A-6CC1-4FFB-89D5-5A8F5C2A5EF8Q28539068-274D7DB8-1198-46D0-A47D-F064CB13D3B7Q28550306-F7939A84-2684-4834-A535-59650C1E0F3DQ28552396-B95E12E5-7614-4118-9CE4-AF139F7E4DE0Q30275257-74246BA1-22C7-44FD-85DB-33A3C7DCB062Q34017586-965D7496-6C46-4365-822B-7E968F3CF105Q34058373-A792E379-D536-4312-B35D-BA2501E2BDFEQ34299023-DAAA70E7-433E-4479-B3C0-E0204ECD8775Q34328882-D89466E9-B70E-4D64-98F8-118D3CFE522EQ34660710-FA2EAB81-B1F1-44AF-A09A-61E07F4AACA1Q34669706-8C37FC48-1469-41EB-B806-A2515065D890Q35834211-8F915470-64DE-46AF-ACA1-9EBBEE5FF609Q36209634-7EF2AB19-50F0-4E52-A43E-64F1194ED489Q36276947-7495FA9B-1532-41E1-8AC9-4213283DA56EQ36589075-BA545252-8347-43AF-BBF1-DE6B686CDBC9Q37376232-F85592A5-CEB7-4D15-B20E-FD82A1E267E6Q37377483-10BCEEB7-DDF6-4A6C-A02F-5012969D45C1Q37378031-BA5B9C3F-981E-4DED-8617-A716AC287926Q37390629-8962CF7D-82B6-4FF3-95CB-CA0229A55244Q38366599-944935DD-F877-4CA2-AF18-9ED8BDFC83F6Q38602559-86322CD9-B966-4E4C-8928-BB661EA00F04Q38930809-BA8A1A7E-D006-498F-BECC-BD9D3F83B230Q39014583-334EAE63-46F3-4ACF-9E77-6EA0AA237D3AQ39429759-A088145B-9042-42E9-A9C8-E31EF54EC94FQ40141972-C7EECB00-7129-4EE0-BCE6-4DDF061D9C7AQ40368271-634474F7-03B2-418E-BFDC-070A04779BB6Q40479825-B8F4B3E1-060B-455D-B9B5-7AB67C5193B7Q40945954-2E522510-C8EB-45EB-88B5-429696897D57Q41562177-9D448C54-B010-4E72-8330-3083ADC4A876Q46275091-E0299325-4A42-4AFE-921F-F2EC28EF47C3Q52744402-6AA2207B-8023-49C2-AC7B-CD06ABECFCB2Q55200404-2C020EAD-D06F-4BAD-B45E-45DD3DC7FB03Q57762628-7902218B-E2DE-4B02-935A-AD8B9C3F8BF4Q58621870-CDE86FC5-761F-43D2-A017-84EF35810608
P2860
Leishmania antimony resistance: what we know what we can learn from the field.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Leishmania antimony resistance: what we know what we can learn from the field.
@en
Leishmania antimony resistance: what we know what we can learn from the field.
@nl
type
label
Leishmania antimony resistance: what we know what we can learn from the field.
@en
Leishmania antimony resistance: what we know what we can learn from the field.
@nl
prefLabel
Leishmania antimony resistance: what we know what we can learn from the field.
@en
Leishmania antimony resistance: what we know what we can learn from the field.
@nl
P2860
P50
P1476
Leishmania antimony resistance: what we know what we can learn from the field
@en
P2093
Bruno Oury
P2860
P2888
P304
P356
10.1007/S00436-011-2555-5
P577
2011-07-29T00:00:00Z